Press coverage about Pain Therapeutics (NASDAQ:PTIE) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pain Therapeutics earned a news impact score of 0.09 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.7085175608234 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Pain Therapeutics (NASDAQ PTIE) traded up 3.70% on Friday, reaching $3.36. The company’s stock had a trading volume of 11,727 shares. The firm’s 50-day moving average price is $3.58 and its 200 day moving average price is $2.31. Pain Therapeutics has a 52-week low of $0.51 and a 52-week high of $4.82. The company’s market cap is $22.16 million.

Pain Therapeutics (NASDAQ:PTIE) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.17. Equities analysts anticipate that Pain Therapeutics will post $1.51 EPS for the current fiscal year.

A number of research firms have weighed in on PTIE. Zacks Investment Research downgraded Pain Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday. Gabelli downgraded Pain Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 17th. Finally, ValuEngine downgraded Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Pain Therapeutics (PTIE) Share Price” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at

About Pain Therapeutics

Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.

Insider Buying and Selling by Quarter for Pain Therapeutics (NASDAQ:PTIE)

Receive News & Stock Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related stocks with our FREE daily email newsletter.